|
Seladelpar 12-Week Topline Data NASH Phase 2b Study |
|
Corporate Presentation |
|
Seladelpar for the Treatment of Primary Biliary Cholangitis, Experience with 25 Cirrhotic Patients |
|
Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects with Hepatic Impairment |
|
Capturing the Experience and Impact of Itch in Patients with Primary Biliary Cholangitis |
